NMN vs NR: Which NAD+ Precursor Should You Take?

Both raise NAD+. They take different routes to get there, and the evidence behind each one is not the same. Here is how to actually choose.

Why This Matters

Say you've read the case for NAD+. You accept that the molecule matters, that levels fall with age, and that you want to try raising yours. You open a shopping tab and immediately hit a wall. There are two main options, they cost about the same, and the marketing for each one insists it's the superior choice.

So which do you buy? Nicotinamide mononucleotide, NMN, or nicotinamide riboside, NR?

I went looking for a clean answer and didn't find one. What I found instead was more useful: a clear picture of what each molecule actually has behind it, where the evidence is strong, where it's thin, and who benefits from you believing one is better. This piece is that picture.

If you haven't yet decided whether NAD+ supplements are worth taking at all, start with our deeper look at what the NAD+ evidence actually shows. This article assumes you've made that call and now want to pick a lane.

Archival Photograph, c. 1961

Same Destination, Different Roads

Here's the part that cuts through most of the marketing. NMN and NR end up in the exact same place. Your cells turn both of them into NAD+.

They just enter the production line at different points. Think of NAD+ assembly as a short series of steps. NR sits one step upstream of NMN. Your cells take NR, attach a phosphate group to it using enzymes called NR kinases, and that converts it into NMN. Then a second enzyme converts NMN into NAD+.

So NMN is one biochemical step closer to the finish line. The NMN industry leans on this fact constantly. "Why take NR when your body just has to convert it to NMN anyway?"

It's a fair point, but it hides a complication. NMN is a bigger, phosphorylated molecule, and phosphate groups carry a charge. Charged molecules don't cross cell membranes easily. So there's a real debate about how NMN actually gets into your cells. One view holds that NMN must first be stripped back down to NR at the cell surface, then rebuilt inside. Another camp, led by Shin-ichiro Imai, reported a dedicated NMN transporter called Slc12a8 that pulls NMN in directly. That finding is real but still contested, and it was shown mainly in the mouse gut, not human muscle.

The honest summary: being one step closer on paper doesn't mean NMN reaches your cells more efficiently. Biology added a tollbooth that the marketing skips over.

What NR Has Going For It

NR's biggest advantage isn't biochemical. It's the paper trail.

The two most-cited human trials of NR were run by academics, not by the company selling it. In 2018, Christopher Martens and colleagues published a placebo-controlled crossover trial in Nature Communications. Healthy adults aged 55 to 79 took 1,000 mg of NR a day for six weeks. Blood NAD+ rose by roughly 60 percent. In the subgroup with mildly elevated blood pressure, systolic pressure dropped by about 9 mmHg, which is a clinically interesting signal worth a larger trial.

In 2019, Yasir Elhassan and colleagues published a tightly controlled study in Cell Reports. Men aged 70 to 80 took 1,000 mg of NR daily for 21 days. The supplement clearly raised the NAD+ metabolome inside their skeletal muscle and shifted gene expression toward a less inflammatory profile.

Neither trial proved NR makes you live longer. Both were small and short. But they share something valuable: no manufacturer designed or ran them. When an independent lab and a company-funded lab report the same effect, you can trust it more.

NR also has a regulatory edge. It has held stable dietary-supplement status in the United States for years, sold most prominently as Tru Niagen by ChromaDex at around 49 dollars a month for 300 mg a day. No legal cloud, a defined dose, and third-party testing.

What NMN Has Going For It

NMN's case rests on being closer to NAD+, plus a growing set of trials, several of which target outcomes people actually feel.

The headline study is Yoshino and colleagues, published in Science in 2021. Twenty-five postmenopausal women with prediabetes took 250 mg of NMN a day for 10 weeks. The NMN group showed improved insulin sensitivity in skeletal muscle, measured with the gold-standard hyperinsulinemic-euglycemic clamp. That's a genuine functional outcome, not just a biomarker.

It comes with a caveat that the NMN industry rarely mentions. The journal later published a formal Comment questioning how meaningful the effect really was, given the small sample and the size of the change. The finding is suggestive, not settled.

More recent NMN work has chased physical performance. A multicenter, dose-dependent trial in healthy middle-aged adults tested 300, 600, and 900 mg per day. NAD+ rose with dose, and six-minute walking distance improved significantly in all three groups versus placebo at 30 and 60 days. Other trials have reported maintained walking speed and better self-reported sleep in older adults.

The pattern: NMN's evidence is newer, often uses higher doses, and reaches for endpoints you'd notice. The weakness is that a larger share of these trials are run or funded by NMN manufacturers, which invites optimistic interpretation.

The Bioavailability Fight

You'll see confident claims that one precursor "absorbs better." Be skeptical of all of them.

Published estimates put oral NR bioavailability somewhat higher than NMN, but the numbers swing widely between studies and methods. A 2025 review in Food Frontiers by Yang and colleagues compared the two across preclinical and clinical data and reached a careful conclusion: the routes differ, the kinetics differ, and no clean head-to-head human comparison settles which delivers more usable NAD+ to the tissues that matter.

Part of the problem is that "raising blood NAD+" and "raising NAD+ in your muscles, brain, or liver" are not the same measurement. Most trials sample blood because it's easy. What happens inside specific organs is far harder to see, and that's where any healthy-aging effect would have to happen.

So when a brand tells you their molecule is more bioavailable, ask: bioavailable where, measured how, in whom? The marketing answer is usually "blood, in a small study we paid for."

Who's Selling What

Follow the incentives and the debate gets clearer.

NR traces to Charles Brenner, who identified it as a NAD+ precursor in 2004. Brenner has long been affiliated with ChromaDex, the company behind Tru Niagen, and he is NR's most vocal scientific advocate.

NMN is associated with David Sinclair at Harvard, one of the most prominent voices in longevity, who co-founded MetroBiotech to develop a proprietary form of NMN. Sinclair champions NMN; Brenner champions NR; and the two have publicly sparred for years.

This matters for how you read the science. When the loudest expert for each molecule also has a financial stake in it, neither is a neutral referee. It doesn't mean either is wrong. It means you should weight independent trials, like Martens and Elhassan for NR, more heavily than studies an interested party designed. We treat this kind of disclosure as central, which is why every article here carries a Funding Transparency section.

The Legal Mess Around NMN

NR has been quietly legal. NMN has not.

In November 2022, the United States FDA removed NMN from dietary-supplement status, citing an ongoing drug investigation tied to MetroBiotech's pharmaceutical program. For nearly three years, NMN occupied a strange gray zone: widely sold online, yet not formally a legal supplement. In September 2025, following a lawsuit from the Natural Products Association, the agency reversed course and restored NMN's supplement status.

If you value a clean regulatory record and consistent availability, that history favors NR. If you don't mind that NMN took a detour through legal limbo, it's now back on the shelf.

So, Which One?

There's no trial that lets me tell you NMN beats NR or the reverse for healthy aging. Anyone who claims certainty is selling something. What I can offer is a framework based on what you weight most.

If you care most about...	Lean toward	Why
Independent human evidence	NR	Martens 2018 and Elhassan 2019 were academic, not manufacturer-run
Functional outcomes you'd feel	NMN	Insulin sensitivity and walking-distance trials, though smaller and often industry-funded
Cost and clean legal status	NR	Stable supplement status, defined dose, around 49 dollars a month
Being one step closer to NAD+	NMN	One fewer conversion, with the membrane-transport caveat
Lowest cost of all	Plain nicotinamide	The original B3, a few dollars a month, rarely marketed but the same family

My read, if forced to pick for a typical healthy adult: NR is the more defensible default today, mostly because its core evidence wasn't produced by the people profiting from it, and because the cost and legal picture are simpler. NMN is a reasonable choice if its performance-focused trials speak to you and you accept the funding caveats. Neither is a proven longevity intervention, and both are far less established than the unglamorous basics of sleep, exercise, and diet.

Whichever you choose, talk to your doctor first, especially if you take other medications or have a history of cancer, since animal data on NAD+ precursors and tumor growth is genuinely mixed.

The Bottom Line

NMN and NR are cousins that arrive at the same molecule by slightly different roads. Both raise NAD+ in your blood. Neither has earned the longevity claims stamped on the bottles.

If you want the choice with the most independent evidence and the fewest complications, NR is the cleaner pick right now. If you're drawn to the trials that measured strength and stamina, NMN is defensible, as long as you read its industry-funded studies with a careful eye. And if you mainly wanted the cellular benefits without the premium price, plain vitamin B3 sits quietly in the same biochemical family for a fraction of the cost.

The molecule matters less than the longevity industry wants you to think. What you eat, how you move, and how you sleep still do more for your NAD+ and your healthspan than any precursor in a capsule.

Frequently Asked Questions

Is NMN or NR better for raising NAD+?

Both raise blood NAD+ reliably, usually by 40 to 100 percent in human trials. No head-to-head study has shown one produces clinically better results than the other for healthy aging. The difference in evidence quality, not raw NAD+ levels, is the more useful basis for choosing.

Can I take NMN and NR together?

Some people do, but there's no good human evidence that combining them beats taking either one alone. Since both feed the same pathway, stacking them mostly raises your cost. If you're going to try a precursor, picking one and tracking how you feel is the more rational approach.

Which is cheaper, NMN or NR?

They're broadly similar. NR as Tru Niagen runs about 49 dollars a month for 300 mg a day. Over-the-counter NMN typically costs 50 to 100 dollars a month. Plain nicotinamide, the original vitamin B3 both descend from, costs only a few dollars a month.

Is NMN legal again?

Yes. The United States FDA restored NMN's dietary-supplement status in September 2025, after removing it in November 2022 during a drug investigation. NR never lost its supplement status during that period.

Will either one make me live longer?

There's no human trial showing that NMN or NR extends lifespan or reverses biological age. Both reliably raise NAD+, but raising a biomarker is not the same as living longer or better. The honest answer is that we don't know yet.

Sources

1. Martens, C.R., et al. (2018). "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications, 9, 1286. Link
2. Elhassan, Y.S., et al. (2019). "Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures." Cell Reports, 28(7), 1717-1728. Link
3. Yoshino, M., et al. (2021). "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, 372(6547), 1224-1229. Link
4. Pirinen, E., Auwerx, J. (2021). "Comment on 'Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.'" Science, 373(6562). Link
5. "The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial." (2022). Link
6. Yang, et al. (2025). "An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR)." Food Frontiers. Link
7. "Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials." (2024). Current Diabetes Reports. Link

Funding Transparency

LSD is editorially independent. We receive no funding from pharmaceutical, supplement, or longevity companies. In the interest of full transparency, here are the relationships behind the research and products discussed above:

• Tru Niagen / NR: Sold by ChromaDex. Charles Brenner, who identified NR as a NAD+ precursor, has a long-standing scientific affiliation with ChromaDex.
• NMN / MetroBiotech: David Sinclair, NMN's most prominent scientific advocate, co-founded MetroBiotech to commercialize a proprietary NMN formulation.
• Source #5 (dose-dependent NMN trial): Industry-affiliated NMN supplementation trials are frequently sponsored by the manufacturers of the tested product. Readers should weight independent academic trials, such as Sources #1 and #2, more heavily.
• Sources #1 and #2 (NR trials): Conducted by academic groups and not designed or run by the product manufacturer.

Related Reading

• NAD+ Supplements: What the Evidence Actually Shows - The fuller case for and against raising NAD+ at all.
• The Supplement Landscape - How to judge any longevity supplement with a skeptical eye.
• The Hallmarks of Aging - Where NAD+ decline fits among the deeper drivers of aging.
• Metabolic Health Fundamentals - The unglamorous basics that outperform most supplements.
• Mitochondrial Health - Why cellular energy production sits at the center of the NAD+ story.

---

This is not medical advice. Talk to your healthcare provider before starting any supplement, especially if you take medications or have a history of cancer.

Written with the help of AI tools, shaped and verified by humans who care about getting this right.